CBD suffering reputational damage from FDA probe and reports of bad labelling

Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference ...

Restricted content. Do you want to read more?